Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dihydralazine→

Dihydralazine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
484-23-1
Molecular formula
C8H10N6
Molecular weight
190.21 g/mol
Drug class
Direct-acting arteriolar vasodilatorhydrazinophthalazine antihypertensive
Mechanism of action
Relaxes arteriolar vascular smooth muscle through effects on intracellular calcium handling and vascular signalling, reducing systemic vascular resistance and arterial blood pressure.
Indications / reported uses
  • Treatment of hypertension in countries where dihydralazine products remain authorised, including selected severe hypertension or pregnancy-related hypertension settings under specialist supervision; availability and indications are jurisdiction-specific

Sources: NLM MeSH — Dihydralazine · PubMed — Dihydralazine antihypertensive pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dihydralazine Environmental Risk Assessment (ERA) (the Dihydralazine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.